What is ABSI stock price today?

ABSI (Absci Corp) stock is trading at $3.58 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is ABSI stock going up or down today?

ABSI stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ABSI stock now?

The decision to buy ABSI depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ABSI a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ABSI based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ABSI stock overvalued or undervalued?

Use our DCF valuation calculator to determine if ABSI is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is ABSI's P/E ratio?

P/E ratio data for ABSI will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is ABSI's market cap?

ABSI (Absci Corp) has a market capitalization of $0.55 billion, making it a small-cap stock.

What is ABSI's price to book ratio?

ABSI trades at a price-to-book (P/B) ratio of 2.90, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does ABSI pay dividends?

ABSI does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is ABSI's dividend yield?

ABSI does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is ABSI stock a good long-term investment?

ABSI's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ABSI's revenue growth rate?

ABSI has shown revenue growth of -0.0% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Profitability metrics for ABSI are available on our dashboard with complete income statement analysis.

What are the risks of investing in ABSI?

Key risks for ABSI include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ABSI compare to its competitors?

Compare ABSI to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ABSI's performance and positioning.

What is ABSI's stock price target for 2026?

Our AI model provides price targets for ABSI based on fundamental analysis: Bull case $4.65 (+30%), Base case $4.12 (+15%), Bear case $3.22 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about ABSI?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ABSI. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ABSI's next earnings report?

ABSI reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ABSI - Absci Corp

NYSE * Health Care * Biotechnology

$3.58

+$0.35 (+10.84%)

About Absci Corp

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.

ABSI Key Statistics

Market Cap

$547.82M

P/B Ratio

2.90

EPS

$-0.84

Revenue Growth

-0.0%

Employees

140

How ABSI Compares to Peers

ABSI is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
ABSI(This stock)	$547.82M	N/A	-0%	0.0%	-
AMGNAmgen Inc	$191.53B	24.9	0%	0.2%	vs AMGN
GILDGilead Sciences	$170.84B	20.3	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$112.22B	28.8	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.35B	18.1	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.91B	20.9	-0%	0.1%	vs BIIB

Absci Corp Company Information

Headquarters: Washington; U.S.A
Website: www.absci.com
Sector: Health Care
Industry: Biotechnology

ABSI - Absci Corp

About Absci Corp

ABSI Key Statistics

How ABSI Compares to Peers

Absci Corp Company Information

ABSI Lician Score

ABSI Financial Snowflake

Upcoming Events for ABSI